Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fetal Blood | 2 | 2009 | 78 | 0.360 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2009 | 245 | 0.340 |
Why?
|
| Blood Cells | 1 | 2009 | 37 | 0.310 |
Why?
|
| Tuberculosis | 1 | 2009 | 127 | 0.290 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2009 | 390 | 0.280 |
Why?
|
| Apoptosis | 1 | 2009 | 1120 | 0.210 |
Why?
|
| Erythrocyte Transfusion | 2 | 2014 | 52 | 0.200 |
Why?
|
| Hospitals, Teaching | 1 | 2014 | 52 | 0.110 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 76 | 0.100 |
Why?
|
| Blood Donors | 1 | 2012 | 21 | 0.090 |
Why?
|
| Blood Platelets | 2 | 2010 | 239 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 498 | 0.090 |
Why?
|
| Plateletpheresis | 1 | 2010 | 7 | 0.080 |
Why?
|
| Blood Preservation | 1 | 2010 | 27 | 0.080 |
Why?
|
| Anemia, Sickle Cell | 1 | 2012 | 101 | 0.080 |
Why?
|
| Blood Proteins | 1 | 2010 | 84 | 0.080 |
Why?
|
| Cryopreservation | 1 | 2010 | 41 | 0.080 |
Why?
|
| Anaphylaxis | 1 | 2010 | 69 | 0.080 |
Why?
|
| Bromcresol Purple | 1 | 2009 | 3 | 0.080 |
Why?
|
| Electrophoresis, Capillary | 1 | 2009 | 10 | 0.080 |
Why?
|
| Antibodies | 1 | 2009 | 144 | 0.070 |
Why?
|
| Serum Albumin | 1 | 2009 | 57 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2010 | 180 | 0.070 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2003 | 299 | 0.070 |
Why?
|
| Cell Line | 1 | 2009 | 1020 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2007 | 122 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2010 | 600 | 0.060 |
Why?
|
| Multiple Myeloma | 2 | 2010 | 3013 | 0.060 |
Why?
|
| Time Factors | 1 | 2010 | 2987 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 2003 | 126 | 0.050 |
Why?
|
| Cattle Diseases | 3 | 1969 | 15 | 0.040 |
Why?
|
| Humans | 8 | 2014 | 52441 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1997 | 35 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1997 | 59 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1997 | 47 | 0.030 |
Why?
|
| Cell Survival | 2 | 2010 | 598 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 1997 | 145 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2003 | 5508 | 0.020 |
Why?
|
| Hypodermyiasis | 2 | 1969 | 2 | 0.020 |
Why?
|
| Skin Diseases, Parasitic | 2 | 1969 | 2 | 0.020 |
Why?
|
| Blood Group Antigens | 1 | 2012 | 4 | 0.020 |
Why?
|
| Blood Group Incompatibility | 1 | 2012 | 4 | 0.020 |
Why?
|
| Missouri | 1 | 2012 | 66 | 0.020 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2010 | 12 | 0.020 |
Why?
|
| Isotonic Solutions | 1 | 2010 | 21 | 0.020 |
Why?
|
| Platelet Transfusion | 1 | 2010 | 33 | 0.020 |
Why?
|
| P-Selectin | 1 | 2010 | 27 | 0.020 |
Why?
|
| Leukocytes | 1 | 2010 | 54 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 2010 | 55 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2010 | 73 | 0.020 |
Why?
|
| Cell Count | 1 | 2010 | 143 | 0.020 |
Why?
|
| Platelet Aggregation | 1 | 2010 | 76 | 0.020 |
Why?
|
| Platelet Activation | 1 | 2010 | 46 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2012 | 351 | 0.020 |
Why?
|
| Graft Survival | 1 | 2010 | 157 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 2010 | 80 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2010 | 479 | 0.020 |
Why?
|
| Female | 5 | 2014 | 28277 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 1576 | 0.020 |
Why?
|
| Theophylline | 1 | 2007 | 20 | 0.020 |
Why?
|
| Insect Repellents | 1 | 1966 | 1 | 0.020 |
Why?
|
| Insect Control | 1 | 1966 | 2 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2007 | 169 | 0.020 |
Why?
|
| Middle Aged | 2 | 2014 | 13133 | 0.010 |
Why?
|
| Models, Biological | 1 | 2007 | 735 | 0.010 |
Why?
|
| Hematocrit | 1 | 2003 | 42 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2003 | 151 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2012 | 4046 | 0.010 |
Why?
|
| Male | 2 | 2014 | 26874 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2003 | 114 | 0.010 |
Why?
|
| Adult | 2 | 2012 | 14205 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 4346 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2003 | 768 | 0.010 |
Why?
|
| Adolescent | 1 | 2012 | 6713 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2007 | 2871 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2003 | 639 | 0.010 |
Why?
|
| Child | 1 | 2012 | 7194 | 0.010 |
Why?
|
| Cattle | 3 | 1969 | 197 | 0.010 |
Why?
|
| Organophosphonates | 2 | 1969 | 6 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2010 | 6694 | 0.010 |
Why?
|
| Anti-Infective Agents | 2 | 1969 | 106 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1997 | 441 | 0.010 |
Why?
|
| Up-Regulation | 1 | 1997 | 462 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2003 | 3449 | 0.010 |
Why?
|
| Larva | 2 | 1969 | 32 | 0.010 |
Why?
|
| Anti-Infective Agents, Local | 2 | 1969 | 29 | 0.010 |
Why?
|
| Aged | 1 | 2003 | 10242 | 0.000 |
Why?
|
| Seasons | 1 | 1969 | 95 | 0.000 |
Why?
|
| Germany, East | 1 | 1966 | 4 | 0.000 |
Why?
|
| Animals | 3 | 1969 | 13485 | 0.000 |
Why?
|
| Antiparasitic Agents | 1 | 1969 | 11 | 0.000 |
Why?
|
| Perfusion | 1 | 1969 | 49 | 0.000 |
Why?
|